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ABSTRACT
A 2008 review by our group concluded that the 
risk of neuropsychiatric adverse events (NPAEs) in 
influenza patients was not increased by oseltamivir 
exposure, and did not identify any mechanism 
by which oseltamivir or its metabolites could 
cause or worsen such events. The current article 
reviews new information on this topic. Between 
September 16, 2007 and May 15, 2010, 1,805 
spontaneously-reported NPAEs were identified in 
1,330 patients receiving oseltamivir: 767 (42.5%) 
from Japan, 296 (16.4%) from the USA, and 
742 (41.1%) from other countries. NPAEs were 
more common in children: 1,072 (59.4%) events 
were in those aged ≤16 years. NPAEs often 
occurred within 48 h of treatment initiation 
(953 events; 52.8%). Nearly half of the events were 
serious in nature (838; 46.4%). The three largest 
categories of events were abnormal behavior 
(457 events, 25.3%), miscellaneous psychiatric 
events (370; 20.5%), and delusions/perceptual 
disturbances (316 events, 17.5%). A total of 
1,545 events (85.6%) in eight different categories 
were considered to be delirium or delirium-like. 
Twenty-eight suicide-related events were reported. 
A US healthcare claims database analysis showed 
that the risk of NPAEs in 7,798 oseltamivir-treated 
patients was no higher than that in 10,411 patients 
not on antivirals, but a study on oseltamivir and 
abnormal behavior in Japan was less conclusive. 
NPAE frequency in oseltamivir-exposed Japanese 
and Taiwanese children with influenza was the 
same as in unexposed children. New analysis of 
the UK General Practice Research Database showed 
that the relative adjusted risk of NPAEs in influenza 
patients was 2.18-times higher than in the general 
population. Other epidemiology studies report 
frequent occurrence of encephalitis and similar 
disorders in influenza patients independently of 
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uses the same structure as the original article, 
but only reports new data. Additional published 
information was identified by a literature search, 
the scope of which was wider than that of the 
2008 review – its aim was to identify reports of 
NPAEs in patients with influenza irrespective of 
treatment with oseltamivir or other antivirals. 
Medline and EMBASE databases were searched 
on January 11, 2011 for publications in English 
that contained the term influenza (and similar 
constructions such as “flu”) and at least one of 
34 terms relating to central nervous system (CNS) 
disorders and symptoms, such as encephalitis, 
loss or depressed level of consciousness, delirium, 
convulsion, hallucination, and abnormal 
behavior. This identified 493 publications, 
abstracts of which were independently screened 
by two experts to exclude those not relevant 
to influenza-associated CNS disorders. The 
94 publications remaining after screening are 
summarized in the appropriate sections below, 
together with other articles that were found 
during the screening and reviewing process and 
deemed to be of relevance.
CLINICAL SAFETY ASSESSMENT
Post-Marketing Reports of NPAEs in the 
Roche Global Safety Database
The 2008 review presented an analysis of 
spontaneously reported NPAEs in the Roche 
Global Safety Database from 1999 to September 
15, 2007. A total of 3,051 events were reported 
for 2,466 patients. To briefly recapitulate, the 
Roche database includes all events reported 
by its affiliates worldwide and by Chugai 
Pharmaceuticals, Roche’s Japanese marketing 
partner. The case definition of NPAEs comprised 
51 MedDRA high-level terms (106 associated 
preferred terms) in three System Organ Classes 
(nervous system disorders, psychiatric disorders, 
oseltamivir exposure. The new data support the 
findings of the original assessment. Evidence 
suggests that influenza-related encephalopathies 
are caused by influenza-induced inflammatory 
responses, but more work is needed to confirm the 
underlying mechanisms.
Supplementary material is available on 
SpringerLink.com.
Keywords: Adverse events; Central nervous 
system;  Inf luenza;  Neuropsychiatr ic ; 
Oseltamivir; Safety; Tolerability
INTRODUCTION 
In December 2008, our group reported 
an assessment of influenza-associated 
neuropsychiatric adverse events (NPAEs) in 
patients who had received oseltamivir [1]. The 
article described the steps taken by Roche to 
assess the prevalence and genesis of such events 
by reviewing a wide variety of data, including 
surveillance of post-marketing spontaneous 
adverse event reports and results of preclinical 
and clinical studies. NPAEs had been known 
to be associated with influenza infection in 
Japanese patients before the introduction 
of oseltamivir [2–4], but reports, principally 
on Japanese patients during 2005/2006, had 
suggested that NPAEs might be associated with 
oseltamivir treatment [5]. The conclusion of 
the 2008 review was that the available data 
did not indicate that the risk of NPAEs in 
influenza patients was increased by exposure 
to oseltamivir, and that there was no obvious 
mechanism by which oseltamivir or its active 
metabolite could cause or worsen such events.
The purpose of the current article is to 
update the 2008 review, by reporting additional 
information generated since the first article was 
written. For ease of comparison, this update 
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occurring in children ≤16 years (Table 1). The 
proportion attributable to children was somewhat 
lower than that reported in the original review 
(72.7%). However, the difference in distribution 
by country compared with the original review 
is substantial: Japanese patients accounted for 
42.5% of all events in the current analysis, a 
much smaller proportion than previously (Japan 
accounted for 90.9% of NPAEs in the first review). 
In the current analysis, patients from the USA and 
from the rest of the world (ROW) accounted for 
16.4% and 41.1% of events, respectively (up from 
6.2% and 2.9% in the original review). Comparing 
this supplementary analysis with the original 
of 2008, crude reporting rates per million filled 
and accidents/injuries). In the 2008 review, 
all NPAEs were grouped into 13 categories to 
align with descriptions in the 9th edition of 
International Classification of Diseases (Table 1), 
and this grouping was repeated for the current 
update. A detailed case review was undertaken 
for all serious NPAEs.
This supplementary analysis of NPAEs covers 
the 32-month period from September 16, 2007 
to May 15, 2010, which included the pandemic 
influenza outbreaks in the southern and northern 
hemispheres in 2009/2010 and previous seasonal 
influenza outbreaks. During this period, 
1,805 NPAEs were spontaneously reported in 
1,330 patients, with 1,072 of these events (59.4%) 
Table 1  Summary of post-marketing neuropsychiatric events in children (aged ≤16 years) and adults receiving oseltamivir 
for influenza treatment or prophylaxis from September 16, 2007 to May 15, 2010













Abnormal behavior 457 (25) 76 (10) 381 (36) 170 (20) 31 (9) 139 (28)
Accident/injury 27 (1) 20 (3) 7 (1) 18 (2) 14 (4) 4 (1)
Cognition disturbance 171 (9) 97 (13) 74 (7) 93 (11) 46 (13) 47 (10)
Convulsions 104 (6) 48 (7) 56 (5) 88 (11) 39 (11) 49 (10)
Delirium 79 (4) 27 (4) 52 (5) 65 (8) 23 (7) 42 (9)
Delusions/perceptual disturbance 316 (18) 121 (17) 195 (18) 164 (20) 70 (20) 94 (19)
Depressed level of consciousness 32 (2) 17 (2) 15 (1) 15 (2) 12 (3) 3 (1)
Encephalitis 27 (1) 10 (1) 17 (2) 27 (3) 10 (3) 17 (3)
Loss of consciousness 37 (2) 29 (4) 8 (1) 19 (2) 15 (4) 4 (1)
Miscellaneous psychiatric 370 (20) 191 (26) 179 (17) 107 (13) 50 (14) 57 (12)
Panic attack 19 (1) 11 (2) 8 (1) 9 (1) 6 (2) 3 (1)
Parasomnia 138 (8) 63 (9) 75 (7) 35 (4) 10 (3) 25 (5)
Suicidal events 28 (2) 23 (3) 5 (0) 28 (3) 23 (7) 5 (1)
Total number of events 1,805 733 1,072 838 349 489
Total number of patients 1,330 523 807 603 249 354
MedDRA terms and associated preferred terms in three classes (nervous system disorders, psychiatric disorders, and 
accidents/injuries) are grouped into 13 categories
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prescriptions (Table 2) fell markedly in Japan, 
from 127 to 55, whereas in the ROW, the rate 
rose more than twofold (210; original review, 92). 
In the USA, the rate fell slightly from 27 to 25. 
The rate increase in the ROW in 2009/2010 
was driven by public health responses to the 
pandemic, notably in the UK, which accounted 
for 36% of all adverse events reported to 
Roche from May 1 to December 31, 2009 [6]. 
A new portal for telephone and internet-based 
reporting of adverse events in the UK was 
introduced by the Medicines and Healthcare 
Products Regulatory Agency on July 23, 2009 and 
operated until February 11, 2010.
As in the original review, more events were 
reported by men than women (957 vs. 737); for 
the remaining 111 events, the patient’s gender 
was unknown. For 663 events, latency was 
unknown, and in the remaining 1,142 events, 
the majority (953 [83.4%]) occurred within 
2 days of starting oseltamivir treatment. This 
proportion was a little higher than reported in 
the original review (i.e., 77.6% of events). Only 
39 patients reported NPAEs (56 events) while 
using oseltamivir for influenza prophylaxis 
(see below) – the remaining patients used it 
for influenza treatment. In all, 838 events (in 
603 patients) were classified as serious (SAEs) 
– as a proportion of the total (46.4%), this 
was considerably higher than in the original 
review (24%). For 601 events, the outcome was 
not reported; of the remaining 1,204 events, 
995 (82.6%) improved or resolved, a slightly higher 
proportion than in the original review (77.6%). 
The reporting rate of deaths associated with NPAEs 
(23/1,805 [1.3%]) was a little higher than in the 
previous analysis (0.6%); 18 of the deaths were 
related to encephalitis or encephalopathy. 
The most common category of NPAEs was 
abnormal behavior, which accounted for 457 
(25.3%) events across all age groups, the next 
most common categories being miscellaneous 
psychiatric events (370 events; 20.5%) 
and delusions and perceptual disturbances 
(316 events; 17.5%). These three categories 
constituted 63% of all NPAEs, a slightly lower 
proportion than in the original review (72%), 
in which abnormal behavior was also the most 
common category (38.0% of all events).
All information in the Roche safety 
database about the NPAE was used to assess the 
relationship between the event in question and 
accompanying fever and diagnosis of influenza 
in those patients who had taken oseltamivir 
as influenza treatment (not as prophylaxis). 
Information on whether fever was present or not 
at the time of the NPAE was missing for 289/457 
(63%) younger patients (aged ≤16 years) and for 
244/289 (84%) adult patients. In patients for 
whom data were available, fever was present in 
121 of 168 (72%) younger patients and in 29 
of 45 adults (64%). Timing of NPAEs relative to 
the influenza diagnosis was recorded in 34% 
of adult cases and 45% of children. The event 
Table 2  Crude reporting rate of post-marketing neuropsychiatric events (events per one million oseltamivir prescriptions), 
from September 16, 2007 to May 15, 2010
Country Number of NPAEs 
Prescriptions 
(million) 
Event rate per million 
prescriptions
Japan 767 14.07 54.5
USA 296 12.03 24.6
Other countries 742 3.53 210.2
NPAEs neuropsychiatric adverse events
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occurred within 2 days of the diagnosis in 129 
of 205 (63%) children and 31 of 98 (32%) adults, 
which is consistent with the information on 
latency of event relative to treatment initiation 
as described above.
Delirium and Delirium-Like Symptoms
For the majority of NPAEs in adults and children 
(1,545/1,805; 85.6%; Table 1), delirium and 
delirium-like symptoms were reported. All events 
in the following seven categories were associated 
with such symptoms: delirium, perceptual 
disturbances, cognition disturbances, depressed 
level of consciousness, panic attacks, parasomnia, 
and abnormal behavior. In addition, most of the 
events in the miscellaneous psychiatric events 
category were associated with delirium and 
delirium-like symptoms. Of the 1,545 events of 
this type, 976 were reported in children (91% of 
all events in children) and 569 in adults (78%), 
and the proportions classified as SAEs were 
similar in children and adults: 410/976 (42%) and 
226/569 (40%), respectively (Table 3). However, 
the association of delirium and delirium-like 
symptoms with NPAE categories in children 
was different to that in adults. In children, they 
were most commonly associated with abnormal 
behavior (39%); delusions and perceptual 
disturbances accounted for 20% and miscellaneous 
psychiatric events for 18% of these symptoms. In 
adults, however, the strongest association was with 
miscellaneous psychiatric events (32%; Table 3).
Accidents and Injuries
All reports of accidents and injuries in the 
safety database were reviewed, whether or not 
they were associated with NPAEs. Twenty-
seven events were reported in 23 individuals 
(seven events in six children); 18 events in 
15 individuals were serious; one of these events 
Table 3  Categorization of delirium and delirium-like events (including serious adverse events) in influenza patients who 




Number of SAEs/number of patients with 
SAEs
Adults Childrenb Adults Childrenb
Delirium 23 (4) 52 (5) 19/19 42/42
Delusions and perceptual 
disturbances
115 (20) 194 (20) 68/63 93/88
Cognition disturbances 88 (15) 73 (7) 38/33 47/37
Parasomnia 61 (11) 75 (8) 10/9 25/25
Abnormal behavior 73 (13) 381 (39) 29/29 139/138
Depressed level of consciousness 17 (3) 15 (2) 12/12 3/3
Panic attacks 10 (2) 7 (1) 6/6 3/3
Miscellaneous psychiatric 182 (32) 179 (18) 44/35 57/44
Total 569 (100) 976 (100) 226/206 410/380
SAEs serious adverse events
a Serious and nonserious 
b Aged ≤16 years
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was in a patient receiving prophylaxis. The 
most common events were falls and contusions. 
In 10 of the 14 influenza patients treated with 
oseltamivir who had SAEs, NPAEs such as 
loss of consciousness, confusion, dizziness, 
and hallucinations were associated with the 
accident or injury. In nine of 12 SAEs for which 
information on timing of the event was available, 
the event occurred early in the disease course 
(i.e., within 48 h of taking oseltamivir). For 10 of 
the 14 serious cases, information was insufficient 
to assess any association between oseltamivir 
exposure and the accident or injury. In two cases, 
comedication and medical history were possible 
confounders, and in two others, influenza was 
the only possible confounder. Information on 
timing of the serious accident or injury relative 
to the development of fever and other symptoms 
was only available for two cases: the first of these 
(contusion) happened within 1 day of the start 
of fever and the other (road traffic accident) 
happened 6 days after the onset of pyrexia.
Suicide-Related Events
The original review reported incidence of 
suicide-related events in patients exposed to 
oseltamivir. An extended search was performed 
of the Roche Global Safety Database for 
spontaneous reports of this type of adverse event 
from the date of the first market authorization 
up to September 17, 2009. A total of 39 cases 
were found, the most common preferred terms 
for the events being suicidal ideation (18) and 
suicidal attempt (8), with five cases of completed 
suicide. The other events were self-injurious 
behavior (5), intentional self-injury (2), and 
self-injurious ideation (1). In eight of the 
39 cases of suicide-related events, information 
on medical history was insufficient; in 12 of 
the remaining 31 cases, psychiatric disorders 
that may have precipitated the event were 
present. Other NPAEs were associated with 
26 (67%) cases – the symptoms reported included 
anxiety, depression, abnormal behavior, sleep 
disorder, hallucinations, phobia, paranoia, and 
delusion. In nine cases, no associated NPAEs 
were reported, and information was lacking in 
the remaining four cases.
The crude reporting rates for suicide-related 
events and completed suicides, respectively, in 
patients exposed to oseltamivir (patient exposure 
of approximately 64.7 million patients) were 
0.060 and 0.008 events per 100,000 patients. The 
reporting rate of completed suicide is markedly 
lower than published rates for completed suicides 
in the general population, which range from 
15 in the UK to 51 in Japan (per 100,000 persons). 
The available data are therefore not compatible 
with oseltamivir having a causal role in suicidal 
ideation and/or suicide in influenza patients.
NPAEs in Patients on Oseltamivir 
Prophylaxis
The analysis of the three seasons from 2007/2008 
to 2009/2010 found that of 1,330 patients who 
reported NPAEs on oseltamivir, 39 (2.9%) were 
taking it for prophylaxis. This fraction is higher 
than in the original review (19/2,466; 0.8%). A 
case review of the 39 prophylaxis patients, in 
whom a total of 56 NPAEs were reported, showed 
that in 22 (56%) cases, there were alternative 
explanations for the event. In the 17 other cases 
(44%), insufficient information was available 
for analysis of causality. A causal link between 
oseltamivir prophylaxis and these events could 
not be established. 
NPAEs IN PROSPECTIVE CLINICAL 
TRIALS OF OSELTAMIVIR
The original review included a summary of NPAEs 
reported during prospective clinical studies in 
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the Roche database, comparing oseltamivir with 
placebo in both treatment and prophylaxis 
indications. In treatment studies, reporting rates 
for oseltamivir (0.5%) and placebo recipients 
(0.6%) were very similar [1], and no new treatment 
studies have been performed since then. However, 
additional prophylaxis studies have been 
completed, increasing the cumulative total of 
patients exposed to oseltamivir in this indication 
to 2,856, of whom 1,902 took part in randomized, 
blinded studies. The updated incidence rates are 
similar to those in the previous review: significantly 
fewer oseltamivir patients (12/1,902; 0.6%) reported 
NPAEs than placebo recipients (20/1,365; 1.5%; 
P < 0.05, two-sided Fisher’s exact test).
NPAEs IN RETROSPECTIVE 
SURVEILLANCE STUDIES 
In the 2008 review, results of three retrospective 
observational studies were summarized. All three 
used health claims data from US databases to 
compare NPAE incidence in a cohort of patients 
receiving oseltamivir and a cohort receiving no 
antiviral treatment, and showed that the use of 
oseltamivir was not associated with a higher risk 
of NPAEs [1]. 
The third of these retrospective studies, an 
analysis of data from two databases (MedStat 
[MS] and United Healthcare [UH]), has been 
extended to include a 6th year of claims data, 
bringing the number of patients per cohort 
to 106,487 and 102,591, respectively, in the 
two databases. Patients in the two cohorts 
(aged >1 year and diagnosed with influenza 
between October 1, 2001 and September 30, 
2007) were matched using propensity scores, 
and incidence of NPAEs was compared across 
12 categories (the same as those used for the 
analysis of spontaneously reported NPAEs, 
omitting accidents and injuries). The analysis 
of this extended dataset produced results very 
similar to those reported in the 2008 review [1]. 
For patients of all ages, incidence rates for most 
of the NPAE categories analyzed were lower in 
the oseltamivir cohort than the no-antiviral 
cohort, and for some categories, the difference 
was significant. Oseltamivir users did not have 
a significantly higher risk of an NPAE in any 
category. For all NPAE categories combined, 
the risk of an event was significantly lower 
with oseltamivir than with no antiviral: 
total incidence rates were 0.62% and 0.97%, 
respectively, in UH (odds ratio [OR] = 0.64; 95% 
confidence interval [CI]: 0.58–0.71) and 0.23% 
and 0.33%, respectively, in MS (OR = 0.72; 
95% CI: 0.61–0.85). In patients ≤16 years old 
(approximately 40,000 per cohort), there was 
no significant difference between cohorts in 
NPAE risk. The total incidence of NPAEs was 
lower in this age group than in the whole 
cohort (all ages): 0.37% (oseltamivir) and 0.45% 
(no antiviral) in UH and 0.20% and 0.19%, 
respectively, in MS. The extended analysis does 
not support a higher rate of NPAEs among 
oseltamivir users than nonusers, and suggests 
that the drug might have a protective effect, 
particularly in adult patients. 
Two observational studies published in 2009 
also found no evidence that oseltamivir treatment 
increases the rate of influenza-associated NPAEs. 
The results of the first study, on patients ≥1 year 
old in the UH database [7], were reported in the 
2008 review [1], as they had been presented at a 
scientific meeting in 2007. In summary, that study 
found a significantly lower incidence of NPAEs 
in the oseltamivir cohort than the no-antiviral 
cohort, a difference that applied to analyses of all 
events, major events, and events specific to CNS 
disorders. In patients ≤17 years old, incidence 
rates in the two cohorts (n = 20,250 and 80,900 
respectively) were not significantly different [7]. 
A new study, not analyzed in the first review, 
was undertaken in children and adolescents 
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(aged 1–21 years) with an influenza diagnosis, 
using data from the US Department of Defense’s 
TRICARE database, which contains healthcare 
information on over 9 million beneficiaries [8]. 
The incidence of all NPAEs was significantly 
lower in the oseltamivir cohort (n = 7,798) 
than the no-antiviral cohort (n = 10,411), with 
rates of 3.0% and 3.8% respectively (P < 0.05). 
Unlike the two analyses described above, groups 
were not matched for propensity scores, but a 
logistic regression analysis that adjusted for this 
factor found a significantly lower risk of events 
in the oseltamivir cohort (OR = 0.82; 95% 
CI: 0.69–0.96). The authors also found the risk 
of an NPAE rose consistently with increasing 
age, whether or not the patient was treated. The 
range of events described as NPAEs in this study 
was similar to that in the Roche safety database 
analysis and in the combined MS + UH study 
reported in the review of Toovey et al. [1], but 
did also include stroke.
The results of a surveillance study conducted 
for the Japanese Ministry of Health, Labor, and 
Welfare during the 2006/2007 season in 10,017 
children and adolescents with influenza aged <18 
years, of whom 7,586 received oseltamivir [9], 
have prompted extensive discussion. The 
author concluded that there was no correlation 
between treatment and abnormal behavior, but 
also noted that interpretation was complicated 
by limitations in the study method, and called 
for a case-control study to confirm the findings. 
According to a conditional logistic model, 
abnormal behavior as a whole was significantly 
less likely during treatment with oseltamivir 
(OR = 0.62; 95% CI: 0.51–0.76), although for 
abnormal behavior that carried a significant risk 
of injury or death, no such treatment advantage 
was shown (OR = 1.25; 95% CI: 0.37–4.23). 
Other researchers subsequently criticized the 
reallocation of patients from the treated to the 
untreated groups in this study: the re-calculation 
by Yorifuji et al. [10] gave rates of abnormal 
behavior of 13.0% and 8.8% in treated and 
untreated groups, respectively (risk ratio = 1.48; 
95% CI: 1.28–1.72), suggesting that oseltamivir 
use was positively associated with such behavior. 
However, since this recalculation itself introduces 
potential biases, as pointed out by Peng and 
Robinson [11], the findings of the original 
surveillance study remain difficult to interpret.
In a retrospective chart review in US infants 
aged <1 year with suspected or confirmed 
influenza [12], abnormal neurological events 
occurred in 19 of 115 (16.5%) infants who 
received oseltamivir (doses of up to 7.0 mg/kg) 
and in a similar proportion of infants who 
received amantadine or rimantadine (17/65; 
26.2%; P = 0.13). The most common event 
(13/22 and 13/18, respectively) was recorded 
as “irritable”, which suggests a mood disorder 
rather than a neurological one; two seizures 
occurred, one in each group [12]. 
REPORTS OF NPAEs IN INFLUENZA 
PATIENTS AND RELATIONSHIP TO 
OSELTAMIVIR TREATMENT
In the 2008 review, five reports from Japan and 
Taiwan on influenza patients aged ≤18 years 
indicated that NPAEs occurring in influenza 
patients were similar whether or not they are 
exposed to oseltamivir, and that many events 
occur before treatment initiation [1]. Since then, 
a paper by Hama [13] was published that presents 
details of adverse events in eight Japanese 
patients who were prescribed oseltamivir, the 
events typically being of sudden onset. The 
events resulted in five deaths, three during 
sleep, and two from accidents associated with 
abnormal behavior. All these cases are recorded 
in the Roche safety database, and review of 
the cases found no conclusive evidence that 
oseltamivir had caused the NPAEs or the deaths. 
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The great majority of data in other recently 
published studies does not support the 
hypothesis that oseltamivir is the cause of 
influenza-related NPAEs. A survey of 2,651 young 
patients (aged <18 years) admitted to hospital 
in Taiwan with influenza found that 74 (2.8%) 
had CNS complications such as encephalopathy 
or seizures at hospital presentation [14]. No 
patient received oseltamivir before symptom 
onset, but in the 17 who received oseltamivir 
after admission, outcomes were not significantly 
different from the 57 untreated patients. In 
a smaller Japanese study of 22 children and 
adolescents hospitalized with influenza and 
with abnormal behavior, such as hallucinations 
and meaningless speech, the clinical course and 
outcomes in children who had CNS symptoms 
after oseltamivir treatment were similar to those 
whose symptoms preceded treatment [15]. In 
another Japanese study of 11 children who had 
delirious behavior within 3 days of the onset 
of influenza, seven had received no antiviral 
therapy, two patients had received oseltamivir, 
and two had received zanamivir, which is poorly 
bioavailable systemically [16].
The literature search identified case reports 
or case series describing NPAEs in 62 influenza 
patients exposed to oseltamivir – the most 
common events were seizures, encephalitis, and 
altered consciousness, and were mainly reported 
in children and adolescents. For 10 of these 
patients, the timing of oseltamivir treatment 
relative to the development of the events was 
not clearly described; eight of 10 patients 
recovered without sequelae [17–20].
Of 52 patients in whom the timing of 
oseltamivir administration relative to the NPAE 
was documented, most (38) received oseltamivir 
after the event had occurred, thus excluding 
the possibility of a causal association between 
oseltamivir and the event. Thirteen of the patients 
were described in single case reports, and the 
other 25 were from 10 case series [17, 18, 21–41]. In 
the other 14 patients (eight from single case reports 
and six from five case series), the NPAE appeared 
or worsened after exposure to oseltamivir [22, 30, 
34, 39, 41–49]. One patient died, a 4-year-old girl 
with chronic renal failure: she started oseltamivir 
on admission to hospital, 3 days after onset of 
influenza symptoms, and developed seizures, 
respiratory arrest, and coma the next day. Her death 
1 day later was ascribed to influenza-associated 
acute necrotizing encephalopathy (ANE) [41]. 
Eleven other patients recovered after the NPAE 
(eight fully, three partially): eight completed 
their oseltamivir treatment, and three did not. In 
the two other patients, CNS complications were 
unlikely to be related to oseltamivir exposure as 
they developed 2–3 weeks after completion of 
oseltamivir treatment. The first of these patients 
had hypoxic brain injury after a prolonged period 
of intubation for hypoxemic respiratory failure 
and the second, who had been intubated for 
20 days for bilateral pneumonia, developed 
agitation and Parkinsonian symptoms on being 
extubated [48, 49]. For three of the 14 patients 
with an NPAE after oseltamivir exposure, the 
authors considered that the NPAE was possibly 
related to oseltamivir. The first of these cases was 
a 35-year-old man who after taking three doses 
of oseltamivir (and within 2 days of the onset of 
influenza) developed a mild encephalopathy with 
a splenial lesion and raised cytokines; oseltamivir 
was discontinued [46]. The second case was a 
15-year-old boy who developed confusion and 
agitation with electroencephalograms (EEG) 
slowing on day 5 of oseltamivir treatment and who 
improved rapidly after treatment had stopped [34]. 
The third case was a 17-year-old, who had a 
generalized seizure after two doses of oseltamivir 
and who recovered with no further seizures; he 
completed a 5-day course of oseltamivir [43]. 
As described in the following sections, raised 
cytokines, splenial lesions, EEG slowing, and 
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seizures have all been reported in influenza patients 
who have not been treated with oseltamivir. 
EPIDEMIOLOGY OF ADVERSE CNS 
EFFECTS IN INFLUENZA PATIENTS 
In the original review, an analysis of patients 
in the UK General Practice Research Database 
(GPRD) over five influenza seasons (2001/2002 to 
2005/2006) provided evidence of an association 
between influenza itself and adverse CNS effects. 
This analysis has now been expanded to include 
data from patients diagnosed with influenza or 
influenza-like illness in two additional seasons 
(October 1, 2006 to March 31, 2007 and October 1, 
2007 to March 31, 2008). The analysis grouped 
NPAEs into most of the same categories as the 
analysis of spontaneously reported NPAEs 
(omitting abnormal behavior, accidents and 
injuries and miscellaneous psychiatric events), 
and calculated incidence rates per 100 person 
months. The relative risk of an NPAE in the 
30 days after diagnosis (adjusted for age, 
sex, and history of NPAEs) was found to be 
2.18-times higher in 85,300 influenza 
patients (11,297 of whom were aged ≤16 
years) than in the total database population of 
2,940,300 patients (95% CI: 1.98–2.40). The 
relative risk of cognition disturbance, delusions 
and perceptual disturbances, convulsions, 
panic attack, and loss of, or depressed level 
of, consciousness was significantly higher in 
influenza patients than controls (by a factor of 
1.38–4.20). Only 82 of all the influenza patients 
analyzed received oseltamivir (nine of those aged 
≤16 years), none of whom had an NPAE [50]. 
More evidence illustrating the incidence 
of NPAEs in influenza patients comes from a 
prospective study by the National Institute of 
Infectious Diseases in Japan [51]. The study 
followed all patients at any medical institution 
during the 2007/2008 influenza season who 
had both influenza-like illness and serious 
abnormal behavior that could cause injury or 
death. Seventy-seven patients were affected by 
serious abnormal behavior in 2007/2008; the 
median age of patients exhibiting such behavior 
was 8 years (range 2–29 years), with 55 (71%) 
being male. The behavior happened within 
2 days of onset of fever in most patients (80%), 
and mostly occurred immediately after waking 
(48/77; 62%). Information on drugs taken (alone 
or in combination) was available for 59 (77%) of 
the patients: 11 (18%) were taking oseltamivir, 
nine (15%) zanamivir, 27 (46%) paracetamol, 
and 19 (32%) took no drugs. The findings are 
further evidence that influenza associated NPAEs 
occur in the absence of oseltamivir, and that the 
general clinical picture is for emergence early in 
the course of the illness.
CHILDREN AND ADOLESCENTS
The literature search identified many reports of 
adverse CNS effects associated with influenza 
infection (both pandemic H1N1 2009 and 
seasonal strains), mainly in children. Some of 
these publications recorded abnormal behavior, 
but most of the events were acute encephalitis 
or encephalopathy, which are recognized 
neurological complications of influenza [1]. 
Some studies in series of young patients reveal 
more about the strength of association between 
influenza and NPAEs, how frequent such events 
are and their typical features, and what factors 
influence susceptibility and mortality. 
In a 5-year survey of children admitted to 
Swedish hospitals with acute encephalitis of any 
origin, influenza was identified as the etiology for 
five of the 93 cases [52], although results of another 
Swedish hospital survey suggest that influenza-
associated encephalitis may not be readily or 
easily recognized [53]. A prospective registry study 
of 311 children admitted to Toronto hospitals 
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with acute encephalitis or encephalopathy found 
that 22 (7%) had influenza, 14 of whom had no 
other pathogens [54]. Abnormalities in EEG are 
a sensitive tool for measuring encephalitis, and 
abnormal slowing of EEG was recorded in many 
children with influenza-associated encephalopathy 
(IAE) or altered mental status [17, 22, 28, 54–57]. 
Seizures are also a common presenting symptom 
in children with IAE or altered mental status 
[17, 24, 27, 43, 54, 56]. Febrile seizures were 
recorded in 20.6% of children hospitalized with 
influenza in a Chinese study [58]. Two other 
Chinese studies in hospitalized children with 
influenza reported an incidence of febrile seizures 
of 27.6% and approximately 18.0%, and incidences 
of encephalopathy of 1.6 and 0.6%, respectively 
[59, 60]. In 13 children admitted to an intensive 
care unit in China with influenza over a 4-year 
period, one had encephalitis [61]. Several recent 
reports on series of children admitted to hospitals 
with pandemic 2009 (H1N1) influenza record 
CNS manifestations (most commonly seizures and 
encephalopathy) as presenting symptoms. These 
typically affected 4–8% of cases [21, 28, 55, 62–65], 
but were more prevalent in children admitted to 
an intensive care unit or needing mechanical 
ventilation [66, 67].
The recent evidence also indicates differences 
in disease features between younger and older 
children who have influenza-related CNS 
complications. The Toronto study found 
neuroimaging abnormalities in five of seven 
children <2 years of age and in three of seven 
children aged ≥2 years [54]. Also, in a survey of 
472 Japanese children with IAE, significantly 
more of those aged ≤5 years (270/343; 79%) 
had convulsions than those aged 6–15 years 
(42/76; 55%) [68]. The younger group in the 
latter study also had a higher incidence of 
hepatic dysfunction (notably mild elevation of 
aspartate aminotransferase levels), more low-
density areas on brain computed tomography 
scans and significantly more sequelae [68]. 
Marked elevations of aspartate aminotransferase 
(≥500 IU/mL) were one of four variables 
that significantly increased mortality risk in 
children aged <15 years with IAE, others being 
hyperglycemia, blood or protein in the urine, 
and diclofenac use [69].
In the studies mentioned above, most or all of 
the patients were infected with influenza A virus 
infections, which reflects the relative prevalence 
of type A and type B viruses. Two reports from 
Taiwan focused solely on CNS events in young 
patients with influenza B infections. In the 
larger study, a survey of 314 patients, 13 (4.1%) 
patients (mean age 5.3 years) had encephalitis or 
encephalopathy, one of whom died [57], and in 
the other study, one of 87 patients aged <18 years 
(1.1%) had encephalitis [70]. Influenza B infection 
was also diagnosed in a 14-year-old Japanese boy 
who injured himself falling from a window after 
symptoms of parasomnia, fever, and fatigue [71]. 
A single case of acute encephalopathy associated 
with influenza C infection was also reported, in 
a 2-year-old Japanese boy, although the outcome 
was not described [72].
Children with more severe influenza 
complications, in particular ANE, continue to 
be the subject of case reports and series. ANE can 
have other etiologies, and a retrospective report of 
22 Japanese children with ANE found that 11 (50%) 
influenza-associated cases had similar pathology to 
11 (50%) noninfluenza-associated cases, although 
brain stem lesions were more common in the 
former group [73]. Outcomes in this study were also 
similar, with four and three deaths (36% and 27%), 
respectively. The high morbidity and mortality rate 
in ANE is reflected in nine single case reports in 
children and adolescents aged 2–12 years old: the 
condition was fatal in four children, and caused 
severe disablement in two of five who survived [29, 
32, 33, 36, 38, 74–77]. An inherited susceptibility 
to ANE has been discovered, characterized by a 
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mutation in the RAN binding protein 2 gene [78], 
and the clinical presentation of two patients thus 
affected has recently been reported [74]. Another 
case report documented a 3-year-old girl with 
marked neurological impairment resulting from IAE 
combined with cerebral vasculopathy and edema 
characteristic of posterior reversible encephalopathy 
syndrome [79].
Adults
In contrast to the experience in Asian countries, 
a survey of hospitalized influenza patients in 
Sweden found that those affected by encephalitis 
were mainly middle-aged men, although cases 
were rare (21 in 11.5 years) [53]. Adults also 
featured in other recent reports of influenza-
related CNS complications. A 2009 survey of 
hospitalized influenza patients in Singapore 
found mild NPAEs, such as seizures, in nine 
patients aged 15–57 years, six of whom were 
≥18 years old [19]. A Chinese case series described 
three adults aged 72–86 years with acute 
encephalopathy [30], and in a Chilean case series 
of six influenza patients with CNS dysfunction, 
three were adults aged 38–65 years [34]. Four other 
recent case reports on adults describe severe acute 
hemorrhagic leukoencephalitis in a 40-year-old 
man [48], a 46-year-old woman with confusion and 
delirium [26], a 39-year-old woman with influenza-
related acute oculomotor nerve palsy [40], 
and a 65-year-old woman with altered mental 
status secondary to influenza-associated posterior 
reversible encephalopathy syndrome with 
cerebral vasculopathy [80]. In a fifth report case, 
a 22-year-old woman with severe pandemic 
H1N1 2009 influenza complicated by pneumonia 
was intubated and mechanically ventilated for 
20 days. On extubation, she developed severe 
agitation, Parkinsonian symptoms such as 
tremor and mask-like face, and hypothalamic 
abnormality [49]. Whether influenza can trigger 
chronic neurological disorders such as Parkinson’s 
disease is uncertain; a recent review that focused 
mainly on influenza pandemics found little or 
no supporting evidence for a link [81], and an 
analysis of the UK GPRD also found no association 
between influenza infections and subsequent 
development of Parkinson’s disease, although the 
risk of Parkinsonian symptoms was significantly 
associated with influenza infection that occurred 
in the previous month and with the number of 
previous influenza episodes [82].
PHARMACOKINETIC PROFILE OF 
OSELTAMIVIR IN THE CNS 
CNS Exposure to Oseltamivir and its 
Metabolite in Animals 
The original review summarized data, mostly 
from animal studies, that show penetration of 
both oseltamivir and its carboxylate metabolite 
into the CNS to be very low [1], and the results of 
our nonclinical studies on CNS pharmacokinetics 
have since been published separately [83]. 
Additional data have since been reported 
from a pharmacokinetic study in adult mice, 
which mapped the distribution of radiolabelled 
oseltamivir and oseltamivir carboxylate after 
intravenous injection. This study found that 
the ratio of concentrations for brain-to-plasma 
were 0.07–0.14 and 0.06–0.13, respectively [84]. 
These results are in general agreement with those 
of preclinical studies that employed a variety of 
methods [83], and somewhat higher than the 
cerebrospinal fluid (CSF)-to-plasma ratios of 0.02–
0.03 found in healthy volunteers [85].
Regulation of Oseltamivir and Oseltamivir 
Carboxylate Levels in the CNS
The influence of a range of transport systems 
on the disposition of oseltamivir and 
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oseltamivir carboxylate in the CNS and their 
pharmacodynamic effect was described in the 
original review. It was noted that P-glycoprotein 
actively transports oseltamivir out of the CNS, 
but active transport of oseltamivir carboxylate 
through the blood-brain barrier (BBB) had not 
yet been reported [1]. Recently, experiments 
using knockout mice and cell culture models 
reported by Ose et al. [86] have demonstrated 
that organic anion transporter 3 (OAT3) and 
human multidrug resistance protein 4 (MRP4) 
play a role in the active transport of oseltamivir 
carboxylate out of the CNS, although the 
relevance to humans is unclear (see below). 
This group also showed that brain distribution 
of oseltamivir carboxylate in MRP4-/- mice 
was higher than in wild-type mice, but the 
distribution in OAT3-/- mice was very similar to 
that in wild-type mice. The authors speculated 
that OAT3 might also mediate transport in 
the opposite direction (into the CNS). The 
authors of this study concluded that oseltamivir 
carboxylate can cross the BBB, but its disposition 
in the brain is limited by active transport 
systems such as OAT3 and MRP4. The nature of 
the interaction between these transport systems 
is still unclear, including how impairment of 
one system, for example as a result of genetic 
variations, might be compensated by another 
system. Additionally, it was reported by Uchida 
et al. [87] that protein expression of MRP4 
and OAT3 in the BBB is different in mice and 
humans, with human values being 8.1 and 
>5.7-times lower, respectively, than in mice. 
These data suggest that, in this case, animal data 
may have limited relevance to humans.
In another recently reported pharmacokinetic 
study, mice with lipopolysaccharide (LPS)-
induced inflammation, which increases the 
permeability of the BBB, had brain concentrations 
of oseltamivir and oseltamivir carboxylate that 
were 2 and 2.7-times those in control mice [88]. 
These limited increases in brain concentrations 
in the presence of LPS-induced inflammation are 
regarded as clinically irrelevant, as there are very 
large safety margins [83, 89].
PHARMACODYNAMIC PROFILE IN 
THE CNS
Animal Studies
Some recent publications suggest that 
oseltamivir may have a stimulant effect in the 
CNS. One study by a US group reported that 
oseltamivir carboxylate facilitated neuronal 
firing in ex vivo rat hippocampal slices [90]; 
however, in a well-controlled study that 
used a similar protocol, the authors were not 
able to replicate this finding [91]. A second 
study, by a Japanese group, reported that 
oseltamivir carboxylate enhanced neuronal 
synchronization in pyramidal cells from the 
rat hippocampus ex vivo [92]. Interpretation 
of observed abnormal behavior in rodent 
hippocampal models is not straightforward, as 
they were initially developed to study learning 
and epilepsy. The reported excitatory properties 
of oseltamivir in these models contrast with 
the findings of pharmacology studies that 
showed no binding of oseltamivir carboxylate 
to a large variety of host targets including 
dopaminergic and glutamatergic targets [89, 93]. 
In addition, in vivo animal studies have 
failed to show excitatory effects of oseltamivir 
and its metabolite either in a proconvulsive 
rodent model, on modulation of hexobarbital-
induced sleeping in rodents, or on hyperactivity 
in rodents, even at very high doses [94]. 
The study described above, which showed 
neuro-excitatory properties of oseltamivir 
carboxylate in rat models, also reported 
enhancement of this effect by ethanol [90]. 
Oseltamivir carboxylate and ethanol also 
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produced hypothermia and altered behavior 
(e.g., changes in righting reflex, although the 
authors acknowledged that the latter were 
difficult to interpret). In addition, synaptic 
transmission in hippocampal slices was shown 
to be facilitated by a combination of oseltamivir 
carboxylate, ephedrine, and caffeine [95]. 
The use of ethanol and stimulants in these 
studies was prompted by the observation that 
Japanese influenza patients sometimes take 
these agents in combination with oseltamivir. 
However, the doses of ethanol used in the first 
rodent study (3.3 g/kg in vivo; 60 mmol/L ex 
vivo) were excessively high and would be highly 
toxic or even fatal in humans. Similarly, the 
concentrations of oseltamivir and its metabolite 
used were much higher than extrapolated 
therapeutic concentrations [89]. The reports 
in the Roche safety database did not indicate 
any concomitant intake of ethanol or ethanol-
containing products (e.g., cough syrups) in 
children experiencing NPAEs. 
Effect on Sleep Parameters 
To investigate the effect of oseltamivir on sleep, 
a placebo-controlled polysomnography study 
was conducted in 31 healthy Japanese adults 
using a crossover design. Sleep parameters and 
EEGs were assessed for four consecutive nights, 
with oseltamivir being given on the 3rd and 4th 
days (75 mg single evening dose on day 3; two 
75 mg doses [morning and evening] on day 4). 
Compared with placebo, the study showed 
no clinically relevant effect on EEGs, on sleep 
parameters, or on normal sleep behavior [96]. 
GENETIC INFLUENCES
As mentioned above, oseltamivir is hydrolyzed in 
the body by human carboxylesterases (HCEs) to the 
active metabolite oseltamivir carboxylate [97, 98]. 
The specific enzyme responsible for the hydrolysis 
is HCE1, found principally in the liver [99]. As 
reported in the original review, this enzyme 
has several naturally occurring polymorphic 
variants that hydrolyze substrate in vitro faster 
or slower than the wild-type enzyme [99], but 
the frequencies of these polymorphisms and how 
they affect oseltamivir hydrolysis in humans are 
not yet known. Since the original review, a new 
publication has reported two more variants of 
HCE1 with greatly reduced hydrolysis capacity 
in vitro [100], but the authors acknowledge that 
these mutations have limited clinical relevance, 
given their rarity. In their recent study on gene 
expression and in vitro hydrolytic capacity of 
HCE1 in liver microsome samples, Yang et al. [101] 
reported that the ratio of exposure to oseltamivir 
carboxylate in children to that in adults in vitro 
was approximately 0.15. This contrasts with the 
findings of an in vitro study, which showed levels 
of HCE1 expression in liver fractions to be low 
only in neonates in their first month of life [102]; 
in children aged 1–9 years old, expression was 
approximately 80% of that in adults. That result 
is consistent with the value of approximately 50% 
from an in vivo pharmacokinetic comparison [103]. 
Yang et al. also reported that the hydrolytic 
capacity of fetal microsomes in vitro, although very 
variable, was about 10% of the adult value [101]. 
A subsequent study reported on oseltamivir 
pharmacokinetics in 20 premature neonates 
(median gestational age, 27.5 weeks; chronological 
age, 1.5–17.5 weeks) who received prophylaxis 
after exposure to pandemic H1N1 [104]. This 
sparse data set shows that premature babies, like 
older infants, probably have sufficient capacity to 
metabolize oseltamivir.
Although the results of these two new studies 
imply that partial or complete failure of the 
hydrolytic capacity of HCEs could happen in 
certain individuals because of genetic or age-
related variation, the oseltamivir concentrations 
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that might be produced by complete absence 
of hydrolysis have not been shown to be 
associated with NPAEs. This was described both 
in the original review and in a more recent 
paper reporting nonclinical studies of CNS 
pharmacokinetics [1, 83].
OTHER POSSIBLE ASSOCIATIONS 
BETWEEN INFLUENZA AND CNS 
DYSFUNCTION
It has previously been suggested that elevated 
levels of cytokines in the plasma are correlated 
with and possibly cause CNS disorders associated 
with influenza [105, 106]. Several papers found 
in the literature search provide additional 
evidence for this hypothesis. In a group of 
children with confirmed influenza, those 
with mild neurological complications (febrile 
seizures in 17 and delirium in 10) were shown 
to have significantly higher serum interleukin 
(IL)-6 levels (medians, 31.2 and 42.3 pg/mL for 
delirium and febrile seizure groups, respectively) 
than those without complications (15.4 pg/mL); 
however, levels of serum tumor necrosis factor 
alpha (TNF-alpha) and soluble TNF receptor1 
(sTNF-R1) were similar in the three groups [56]. 
Cytokine elevation was also noted in case 
reports of acute encephalopathy and ANE 
[30, 72, 76], and elevation of IL-6 was shown 
to mirror abnormal EEG changes in influenza-
infected rats with induced hyperthermia [107]. 
Other workers have shown that LPS-
induced brain lesions in mice are enhanced 
by pulmonary infection with influenza A 
virus [108], producing hypercytokinemia, 
microhemorrhage, and an increase in BBB 
permeability. Rats with acute peripheral 
inflammation exhibited a marked but reversible 
inflammatory response in the hippocampus, 
characterized by reactive microglia, increased 
TNF-alpha levels, and increased susceptibility 
to pentylenetetrazol-induced seizures [109]. It 
is not yet clear how hypercytokinemia triggers 
CNS changes, although one group recently 
showed that a rise in plasma TNF-alpha in 
mice triggered rises in brain levels of matrix 
metalloproteinase-9 and increases in BBB 
permeability [110]. Another mechanism through 
which elevation of cytokines in the plasma 
could trigger acute phase responses in the 
CNS has been suggested by Serrats et al. [111]. 
They showed that intravenous challenge with 
IL-1 activated perivascular cells in the cerebral 
vasculature, resulting in activation of the 
hypothalamic-pituitary axis and the febrile 
response system, despite a functional BBB; LPS 
challenge also activated this system, producing 
even stronger hypothalamic-pituitary axis 
activation and febrile response [111]. The 
upregulation of systemic immune pathways, 
whether by viral infection or other stimulus, 
is known to significantly affect CNS function 
in Alzheimer’s disease and multiple sclerosis 
[112, 113], and cytokines may play an important 
role in the pathogenesis of depression [114] and 
sleep disorders [115].
Several groups report reversible splenial 
lesions of the corpus callosum in patients with 
IAE, possibly caused by intramyelinic edema 
or inflammatory cell influx, but the exact role 
played by such lesions in the pathogenesis of 
NPAEs is unclear. The splenial lesions may be 
accompanied by EEG abnormalities [16, 116] 
or raised cytokine levels [46], and may result in 
mild CNS disorders in some younger patients 
[117–119]. A 14-year-old boy treated with the 
inhaled topical agent zanamivir had neurological 
symptoms, such as dysarthria and dysphagia, 
associated with a reversible splenial lesion 5 days 
after influenza onset [119]. A speech disorder in 
a boy with influenza and a splenial lesion was 
attributed by the authors to dysarthria of non-
neurological origin [120]. An isolated report of 
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postinfluenza pneumocephalus in a 9-year-old 
boy causing delirium, convulsions, and coma 
suggested that this could be an under-recognized 
mechanism for CNS symptoms in patients with 
recurrent coughing or sneezing [121].
Two reports found in the literature search 
show that invasion of cells by influenza 
virus results in apoptosis [122, 123], but 
only one of these studies was undertaken in 
nerve cells. Apoptosis would be expected to 
result from inflammatory changes such as 
hypercytokinemia, but as the influenza virus 
and viral RNA are rarely found in the brain or 
CSF of patients with IAE, direct viral invasion 
of CNS cells would be unlikely to trigger 
apoptosis [3, 30, 124, 125]. In IAE, however, 
the peripheral blood and CSF concentrations 
of a number of cytokines and their receptors, 
including IL-6, IL-1beta and sTNF-R1, are not 
only raised but also related to severity [126]. 
CNS hypercytokinemia in the absence of direct 
CNS invasion is a possible mechanism to explain 
the pathogenesis of IAE.
Other recent literature reports have identified 
possible genetic risk factors for CNS dysfunction. 
A recent study by Neilson et al. [78] showed 
that missense mutations in RAN binding 
protein 2 increased susceptibility to ANE in 
both individuals and families; individuals with 
this gene mutation are predisposed to develop 
this condition after an environmental trigger 
such as influenza and other infections. Two 
Japanese groups have reported polymorphisms 
in the enzyme carnitine palmitoyltransferase II 
in patients with encephalopathy secondary 
to infectious disease [127, 128]. In patients 
with IAE, who expressed variants of carnitine 
palmitoyltransferase II, energy metabolism 
in mitochondria was impaired, which could 
contribute to brain edema via increased BBB 
permeability [128]. These findings are in line 
with previous reports that carnitine metabolism 
was impaired in many patients with severe 
IAE [129], and that serum concentrations of 
the mitochondrial protein cytochrome C can 
predict the severity of encephalopathy [130]. 
Another metabolic mechanism that could be 
linked to CNS damage is the presence of organic 
acidemias, inherited metabolic disorders, which 
were found in a small proportion of children 
with IAE [131].
The neuro-inflammatory and systemic 
changes mentioned above such as cytokine 
induction and alterations in BBB integrity are 
compatible with the types of injury observed, 
as is the disruption of mitochondrial energy 
metabolism, which is accompanied by neuronal 
oxidative stress and dysfunction, or in some 
cases, apoptosis. It is possible that individuals 
prone to mitochondrial dysfunction might be 
more susceptible to neuronal dysfunction and 
apoptosis in the presence of influenza-induced 
fever or cytokines. This is an area where further 
research would be helpful. 
CONCLUSIONS 
The analysis of spontaneously reported NPAEs 
over the three consecutive influenza seasons 
to May 2010 confirms the results of the 2008 
review. In 83% of NPAE cases, the onset of 
these events was within 2 days of both the 
influenza diagnosis and the start of oseltamivir 
treatment. These associations in timing are a 
logical consequence of the recommendation 
to start oseltamivir treatment within 48 h of 
symptom onset, but have also led to claims 
that the treatment could have caused NPAEs. 
However, NPAEs also coincided to a large 
degree with the occurrence of fever. A close 
temporal relationship between the diagnosis of 
influenza and the onset of NPAEs is also seen 
in cases without oseltamivir exposure, as well 
as in patients exposed to zanamivir, which is 
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not systemically bioavailable, pointing to a 
disease-associated process as pathogenesis. This 
is supported by the findings of clinical reports 
from some Asian countries, by an expanded 
analysis of a large general practice database, 
and by the results of more large observational 
studies in the USA (in children, adolescents, and 
adults) that did not show NPAE incidence to be 
increased by oseltamivir administration.
Reports from recently published literature on 
influenza patients who had CNS complications 
and received oseltamivir, show that in the 
majority of cases, the adverse events happened or 
developed before drug administration, and were 
not exacerbated by subsequent administration. 
Mild encephalopathy was also reported in a 
patient treated with zanamivir, which is not 
absorbed systemically to significant levels [119]. 
In nine cases where events happened or 
worsened after oseltamivir treatment, six were 
not considered to be drug-related, and NPAEs 
in the other three included symptoms such as 
seizures and EEG slowing, which are known to 
be associated with influenza infection itself, as 
described earlier.
In the authors’ analysis of accidents and 
injuries in the Roche safety database, most 
of the SAE cases had an association with an 
NPAE, but reports were not detailed enough 
for the relationship with oseltamivir exposure 
to be assessed. A survey of Japanese health 
insurance claims data in 140,800 influenza 
patients of all ages (of whom 51,505 
received oseltamivir) found that a total 
of 97 injuries occurred in the 3 days after 
influenza diagnosis, and that the crude 
incidence of injuries was significantly lower 
in oseltamivir-treated patients (4.7 per 10,000) 
than in untreated patients (8.2 per 10,000; 
P = 0.015) [132].
Our updated literature search found no 
evidence from animal pharmacology studies 
that oseltamivir can produce harmful CNS 
effects, even at doses markedly higher than 
those typically used in clinical practice. Studies 
completed since the initial review confirm that 
the penetration into the CNS of oseltamivir and 
its active metabolite is low in animals, and it 
is unlikely that changes in the disposition or 
metabolism of oseltamivir in the brain, whether 
caused by genetic polymorphisms or other 
means, can markedly increase exposure to the 
drug. Even if this were to occur, recent studies 
showing lack of interaction with relevant CNS 
targets [89, 93], lack of interference with sleep 
in humans [96], and lack of excitatory effects 
in animals [94]  suggest there would be no 
functional implications of such changes. 
As reviewed above, more evidence has been 
accumulated for influenza-induced inflammatory 
responses and metabolic derangement being the 
most likely causative mechanisms for influenza-
related neuropsychiatric dysfunction. Changes 
due to peripheral inflammation during influenza 
may induce neuro-inflammation and apoptosis 
in CNS tissue, and elevated levels of some 
cytokines continue to be observed in patients 
with neurological complications of influenza. 
Indeed, a recent article by two US neurologists 
proposes that “cytokine storms,” resulting 
from dysregulation of the immune system, are 
the most likely mechanism to explain these 
conditions [133]. The additional surveillance 
data and published evidence on influenza 
patients treated with oseltamivir have still not 
furnished any evidence for a causative link 
between exposure to drug and generation or 
worsening of NPAEs.
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